IMR Press / EJGO / Volume 21 / Issue 4 / pii/2000202

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Retinoids in breast cancer prevention and treatment. A review of the literature

Show Less
1 Clinics of Obstetrics and Gynecology, Dept. of Medical Sciences, University of Eastern Piedmont “A. Avogadro” and “Ospedale Maggiore di Novara”, Novara, Italy
2 Laboratory of Cell Biology, Dept. of Biology and Genetics, University of Torino, Torino, Italy
3 Postgraduate School of Oncology, University of Torino, Torino, Italy
4 Health Care Professional, University of Ancona, Ancona, Italy
5 Institute of Biology and Genetics, University of Ancona, Ancona, Italy
Eur. J. Gynaecol. Oncol. 2000, 21(4), 411–415;
Published: 10 August 2000

During the last three decades, research focused on cancer treatment has led to the development of many cytotoxic agents. Despite the fact that these efforts have significantly improved the prognosis of certain malignancies such as some lymphomas, leukemias and testicular carcinomas, other tumors such as ovarian, lung and metastatic breast cancer are still associated with a poor prognosis. An innovative approach has recently emerged, thanks to a better understanding of tumor cell biology and many efforts are aimed at finding compounds capable of restoring a more differentiated phenotype to tumor cells, thereby reducing the tumor’s aggressiveness and ultimately reverting it to its normal counterpart. Retinoids are the prototype of this new therapeutical approach called “differentiation therapy”.

Breast cancer
Back to top